N eovascularization gene therapy has been proposed as a rescue for ischemic disease. 1, 2 After successful application in animal models, the strategy has been transferred from the bench to the bedside. However, clinical results have not matched the level of efficacy for which researchers had hoped. [3] [4] [5] [6] [7] The serious side effects derived from the use of robust infecting doses of viral vectors and unregulated expression of angiogenic genes 7, 8 point to the necessity that clinical application must be preceded by in-depth clarification of the involved pathways and improvements in the therapeutic-risk index. Furthermore, simple initiators of angiogenesis may not represent the best option to construct a durable and well-tempered neovascularization. In this area of high medical need, substances capable of successfully completing the angiogenic process appear more suitable to the task.
The serine protease human tissue kallikrein (hTK), a recent entry in the angiogenic factor family, has shown promise for the treatment of ischemic disease. Kallikreinkinin system components are upregulated in animal models of and in patients with peripheral vascular disease, 9, 10 and local hTK gene delivery enhances native neovascularization and accelerates tissue healing. 9 It is noteworthy that hTK does not require an ischemic environment for its curative properties. 11 At present, information about molecular effector(s) of adenovirus (Ad) hTK-induced neovascularization remains largely incomplete, being mainly limited to the basic notion that kinins generated by hTK play a fundamental role in these vascular effects. 9 In addition, from in vitro studies we know that bradykinin (BK) activates endothelial NO synthase (eNOS) through either the phosphoinositide 3-kinase-Akt/protein kinase B (Akt-B) pathway or calcineurin-mediated mechanisms. 12 Furthermore, vascular endothelial growth factor (VEGF)-receptor 2 (R2) transactivation by the BK-B2 receptor seemingly induces endothelial cell (EC) tube formation on Matrigel through eNOS mediation. 13 In general, VEGF-A and Akt-B cooperate in the control of endothelial growth and viability, 14 but recent evidence supports the possibility that Akt-B may be activated by alternative pathways independent of VEGF-A. 15 Therefore, we considered it worthwhile to clarify whether hTK stimulates angiogenesis in vivo through Akt-B, eNOS, and VEGF-A. In view of future clinical use, we also evaluated an optimal gene transfer modality, the composition and persistence of neovascularization, and the microvascular permeability of Ad.hTKinfected muscles.
Methods hTK Gene Delivery and Histological Assessment of Muscular Neovascularization
Procedures complied with the standards stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, Md, 1996) .
A dose-response curve (10 3 to 10 9 plaque-forming units [PFU]) to Ad.hTK was established in CD1 mice (Charles River, Calco, Italy). Anesthetized (2,2,2-tribromoethanol, 880 mmol/kg IP, Sigma) mice received 3 injections (3.5 L/injection, 10.5 L total volume) at different sites of the left adductor muscle along the projection of the femoral artery. This procedure enabled Ad vector diffusion along the entire mouse adductor. Ad carrying the luciferase gene (Ad.Luc) and saline served as controls. Each group consisted of at least 6 mice.
Two or 8 weeks after gene transfer, limb muscles were perfusion-fixed and processed for histological analyses of capillary and arteriole density, as described. 11 Capillary density was expressed as capillary number per area (n cap /mm 2 ) of transverse section or normalized to myofiber density (n cap /n fiber ). Arteriole density was expressed as arteriole number per area (n art /mm 2 ). 11 The effect of Ad.hTK on EC proliferation in vivo was evaluated. To this aim, adductors (nϭ5 per group) that had received Ad.hTK or Ad.Luc (each at 10 8 PFU) 3 days in advance were processed for immunohistochemical identification of proliferating cell nuclear antigen (PCNA) by using a monoclonal antibody (Dako). Total capillaries and PCNA-positive ECs were counted in at least 25 fields at ϫ1000 magnification, and the number of PCNA-positive ECs per square millimeter and for every 1000 capillaries was calculated.
Transgene Expression After Ad.hTK Gene Transfer
We established the relation between Ad infecting dose and transgenic protein content. An ELISA (AngioProgen) selectively recognizing hTK 16 was used to measure hTK content in plasma and adductors (nϭ4 per dose) at 5 days from gene delivery, ie, at the peak of transgene expression. 16 Saline-injected muscles served as controls. We also measured hTK levels in the eyes (a tissue at risk for pathological angiogenesis) of mice receiving intramuscular Ad.hTK (10 9 PFU) or saline. Total protein concentration was measured by the Lowry method.
The cellular localization of transgenic protein in infected muscles was determined by immunohistochemistry with a polyclonal rabbit antibody that recognizes exclusively the hTK form. 17 Specific binding was detected with the biotin-streptavidin LSABϩ system (Dako). Controls included preabsorption of anti-hTK with purified human urinary TK (Calbiochem) and replacement of anti-hTK antibody by nonimmune serum at the same dilution. Muscles injected with Ad.Luc and sterile saline served as negative controls.
Microvascular Permeability
Plasma protein extravasation (PPE) provoked by angiogenesis therapy may cause local edema. 18 Because kinins may cause similar reactions, 19, 20 we tested whether this undesired effect occurs after hTK application. Muscular PPE at 3 or 14 days after 10 9 PFU of Ad.hTK or Ad.Luc administration or saline was determined by the Evans blue method 20 and normalized to PPE in the contralateral, noninjected adductors. BK (10 g/10 L IM, given 5 minutes before Evans blue dye) served as positive control. Each group consisted of 6 mice.
Molecular Pathways Activated by Ad.hTK In Vivo

Akt-B Phosphorylation
Western blot analysis of Akt-B was performed on muscles harvested 3 days after 10 8 PFU Ad.hTK or Ad.Luc (nϭ6 each group) had been administered. Twenty-six micrograms of protein for each sample was loaded. The reaction was carried out using primary antibodies raised against Ser-473-phosphorylated or total Akt (Cell Signaling Technology). Tubulin served as the loading control. Specific protein was detected by chemiluminescence reaction (Amersham), followed by analysis of immunoblot density by dedicated software (Scion Corp).
eNOS Expression: Real-Time PCR Primers
Real-time quantitative polymerase chain reaction (PCR; ABI PRISM 7000 sequence detection system software version 1.0, Perkin-Elmer) was used to determine eNOS mRNA content in muscles (nϭ6 per group) harvested 3 days after the injection of 10 8 PFU Ad.hTK or Ad.Luc. Total RNA was isolated with TRIzol reagent (Invitrogen) and treated with DNAse (Qiagen). RNA was reverse-transcribed with M-MLV reverse transcriptase (Invitrogen). eNOS and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer sequences were designed on GenBank database NM-008713 and NM-008084, respectively, and were as follows: 5Ј-CCTTCCGCTACCAGCCAGA-3Ј (eNOS forward), 5Ј-CAGAGATCTTCACTGCATTGGCTA-3Ј (eNOS reverse), 5Ј-CGT GGG GCT GCC CAG AAC AT-3Ј (GAPDH forward), and 5Ј-TCT CCA GGC GGC ACG TCA GA-3Ј (GAPDH reverse). Conventional PCR products of murine eNOS (105 bp) and GAPDH (156 bp) were obtained with the primers designed for the real-time PCR and were cloned into pGEM-T Easy vector (Promega) to be used as DNA standards. eNOS cDNA level was normalized to GAPDH cDNA level.
Muscular eNOS protein content at 5 days from gene transfer was analyzed by Western blotting (nϭ6 muscles per group) with a rabbit polyclonal antibody (1:1000, Santa Cruz). Blots were reprobed with anti-␤-actin antibody (1:1000, Santa Cruz). Immunoblot density was analyzed by Image Gauge V3.41 (Fuji Film).
VEGF-A and VEGF-R2
VEGF-A mRNA content was determined on the same samples used for the eNOS experiment. VEGF-A primers (designed on GenBank M95200) generate a 111-bp fragment and were as follows: 5Ј-CCA GCG AAG CTA CTG CCG TCC A-3Ј (forward) and 5Ј-ACA GCG CAT CAG CGG CAC AC-3Ј (reverse).
Western blots for VEGF-A (rabbit polyclonal antibody at 1:2000, Santa Cruz), VEGF-R2 (goat polyclonal antibody at 1:2500, R&D Systems), and Tyr-951-phosphorylated VEGF-R2 (rabbit polyclonal antibody at 1:1000, Cell Signaling) were performed on the same samples (nϭ6 per group) used for eNOS analysis. After phospho-VEGF-R2 analysis, the membrane was stripped and reprobed with antibody for total VEGF-R2. In all cases, ␤-actin was used for normalization. 
NOS Inhibition
Capillary and arteriole density was counted at 2 weeks from Ad.hTK or Ad.Luc administration (each at 10 9 PFU) in combination with the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME, 1.4 mmol/kg body weight daily in drinking water) or the inactive enantiomer D-NAME. Each group consisted of 6 mice.
Inhibition of VEGF-A Action
The role of VEGF-A was addressed by 3 approaches: (1) A VEGF-A neutralizing antibody (2.5 g IP twice a week, R&D Systems) 22 . Soluble VEGF-R1 is able to entrap several VEGFs, including VEGF-A. Therefore, it inhibits the biological effects of VEGF-A.
The capacity of VEGF-A antibody, PTK 787, or Ad.s-flt-1 to block VEGF-A-induced neovascularization was confirmed by using them or their respective controls (nonimmune IgG, normal drinking water, or Ad.Luc) in mice whose muscles were infected with Ad.VEGF-A (10 7 PFU). Mice (nϭ6 per group) were humanely killed at 14 days from gene transfer for evaluation of neovascularization.
Akt-B Involvement in BK-Induced EC Proliferation In Vitro
We evaluated whether Akt-B blockade by wortmannin inhibits the BK-induced proliferation of human umbilical vein ECs (HUVECs). Proliferation was evaluated by MTS assay (Promega). HUVECs were seeded on 96-well plates. After 4 hours, the medium was changed to medium 199 containing reduced fetal bovine serum (2%) plus wortmannin (10 nmol/L) or vehicle (phosphate-buffered saline). To avoid BK degradation, the angiotensin-converting enzyme inhibitor captopril (10 Ϫ5 mol/L) was added 2 hours before BK (10 Ϫ12 to 10 Ϫ8 mol/L) or its vehicle. Proliferation was assessed after 48 hours. Each experiment was repeated 8 times.
Statistical Analysis
Results are expressed as meanϮSEM. Multivariate repeatedmeasures ANOVA was performed to test for interaction between time and grouping factor. In multiple comparisons in which ANOVA indicated significant differences, the statistical value was determined according to the Bonferroni method. Differences within and between groups were determined by a paired or unpaired Student t test, respectively. A probability value Ͻ0.05 was interpreted to denote statistical significance.
Results hTK Protein Expression
As shown in Figure 1A , muscular hTK protein increased dose-dependently after Ad.hTK administration. hTK was not detected in plasma, contralateral noninjected muscles, or eyes. Skeletal myocytes expressed transgenic protein in variable amounts that in some cells appeared as small dots, whereas in others it was associated with the cell membrane ( Figure 1B, i and ii) . No immunoreactivity was observed in muscles injected with saline or Ad.Luc or when anti-hTK antibody was preabsorbed with the purified human enzyme ( Figure 1B, iii and iv) or replaced by nonimmune serum (not shown). At 14 days from gene transfer, Ad.hTK increased capillary and arteriole density in a dose-related manner (see Figure 2A and 2B). The plateau was reached with 10 7 PFU, indicating that moderate infecting doses are sufficient to elicit maximal biological effect. Results were confirmed after normalization by myofiber density (data not shown).
Previously, we reported that Ad.hTK-promoted capillarization is stable for up to 4 weeks, a time by which transgene expression has expired. 9, 16 Here, we examined the destiny of newly formed vessels over a longer period. At 8 weeks, capillary density of Ad.hTK-injected tissue had returned to the levels of Ad.Luc-or saline-injected muscles ( Figure 2C ). In contrast, arteriole density remained elevated ( Figure 2D) , with the increase encompassing vessels of any size of luminal diameter (data not shown).
As expected, Ad.hTK increased EC proliferation (9Ϯ3 versus 2Ϯ2 PCNA-positive ECs/mm 2 in Ad.Luc and 12Ϯ3 versus 5Ϯ1 PCNA-positive ECs in every 1000 capillaries at 3 days after injection; PϽ0.05 for both comparisons). Data Supplement Figure I (available online only at http://www. circulationaha.org) shows representative images of PCNAstained sections from muscles injected with Ad.hTK (B) or Ad.Luc (A).
Ad.hTK Gene Transfer Does Not Alter Microvascular Permeability
Ad.hTK did not increase PPE (data not shown), whereas the positive control BK increased PPE by 4.96-fold (PϽ0.01).
Ad.hTK Stimulates Akt-B Phosphorylation
As shown in Figure 3 , Ad.hTK augmented Akt-B phosphorylation in Ser-473-treated preparations (PϽ0.01 versus Ad.Luc treated or untreated). Ad.hTK did not change the ratio between total Akt-B and tubulin (data not shown).
Ad.hTK Upregulates eNOS Expression
Ad.hTK increased eNOS mRNA by 2.84 times (PϽ0.05 versus Ad.Luc, Figure 4A ). As shown in Figure 4B , Ad.hTK also augmented eNOS protein content (0.15Ϯ0.02 versus 0.09Ϯ0.01 eNOS/␤-actin ratio in Ad.Luc, PϽ0.05). 
Ad.hTK Does Not Affect VEGF-A Expression
Functional Implication of Akt-B and eNOS in hTK-Induced Neovascularization
Ad.hTK-induced neovascularization involves both Akt-B and eNOS. In fact, hTK-induced angiogenesis and arteriogenesis were significantly inhibited by either Ad.DN-Akt-B ( Figure  5A and 5B) or L-NAME ( Figure 6A and 6B).
hTK-Induced Angiogenesis Is Independent of VEGF-A
As shown in Data Supplement Figure II 
Akt-B Mediates BK-Induced HUVEC Proliferation In Vitro
The Akt-B inhibitor wortmannin reduced BK-induced HUVEC proliferation (data not shown).
Discussion
Our study documents that a low infecting dose (10 6 PFU) of Ad.hTK was sufficient to promote capillary and arteriole growth in limb muscle. With 10 7 PFU, microvascular density was further augmented. No additional effect occurred with escalating doses despite incrementally increased immunoreactive hTK. Our findings introduce the novel concept that low-dosage gene transfer could be effectively applied in vascular medicine with obvious reduction of side effects. This advantageous property could be conferred by the presence of a secretory signal in the hTK encoding sequence, allowing release of recombinant protein from infected cells into the extracellular environment. 24 Thus, a few transduced cells are enough to release an optimal amount of hTK for the desired biological effect to be achieved. Moreover, the enzymatic nature of hTK allows a reduction in infection levels, inasmuch as single molecule of enzyme generates angiogenic kinin effectors continuously. It should be cautiously noted that gene transfer efficiency could be reduced in aged or diseased animals. 25 However, low-dosage Ad.hTK showed the capacity of preventing muscular microangiopathy in type I diabetic mice. 11 Ad.hTK encodes for a pre-pro form of tissue kallikrein. Activation to the mature enzyme was demonstrated in a previous study, where we found increased kinin levels in Ad.hTK-infected, normoperfused mouse adductors. 16 Moreover, the ELISA used in the present study is able to recognize only active kallikrein. 
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